Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ECP002A (delta-9-THC) for spasticity and pain in progressive multiple sclerosis
NL-OMON37947Phase 2Active, not recruiting
- Sponsor
- Echo Pharmaceuticals
- Start
- Mar 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing ECP002A with Placebo (2 arms). Primary endpoint: H-reflex/M-wave amplitude ratio. Started Mar 2011; status: active, not recruiting.
02
Drugs
dronabinol
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON37947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37947.